Skip to main content
. 2021 Jul 8;58(1):2001518. doi: 10.1183/13993003.01518-2020

TABLE 1.

Home spirometry measurements per subject over 52 weeks

Nintedanib Placebo/nintedanib# All subjects
Subjects 116 230 346
Home spirometry measurements
 Mean±sd 157±106 170±119 165±115
 Minimum 3 3 3
 Median 125 136 132
 Maximum 362 633 633

Data are presented as n, unless otherwise stated. #: subjects received placebo (blinded) for 12 weeks followed by open-label nintedanib for 40 weeks.